We are live on ! Find out more
NYMX

Nymox Pharmaceutical Corp

Delisted

NYMX was delisted on the 6th of July, 2023.

29 hedge funds and large institutions have $1.99M invested in Nymox Pharmaceutical Corp in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

3% less funds holding

Funds holding: 3029 (-1)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

20% less capital invested

Capital invested by funds: $2.48M → $1.99M (-$496K)

62% less call options, than puts

Call options by funds: $593K | Put options by funds: $1.54M

Holders
29
Holders Change
-1
Holders Change %
-3.33%
% of All Funds
0.72%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
5
Reduced
5
Closed
6
Calls
$593K
Puts
$1.54M
Net Calls
-$950K
Net Calls Change
-$1.28M
Name Holding Trade Value Shares
Change
Change in
Stake
NFG
26
Next Financial Group
Texas
$5K
ClearBridge Investments
27
ClearBridge Investments
New York
$3K
Wells Fargo
28
Wells Fargo
California
$3K
Bank of Montreal
29
Bank of Montreal
Ontario, Canada
$1K -$42.1K -13,575 -98%
MCM
30
Marathon Capital Management
Maryland
-$179K -55,000 Closed
Citadel Advisors
31
Citadel Advisors
Florida
-$101K -32,661 Closed
N
32
Natixis
France
-$57K -17,600 Closed
AG
33
Advisor Group
Arizona
-$26.8K -8,645 Closed
Walleye Trading
34
Walleye Trading
New York
-$4K -1,200 Closed
IA
35
IFP Advisors
Florida
-$1K -440 Closed

NYMX Hedge Fund Activity: Q4 2016 in Review

29 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q4 2016, worth a combined $1.99M — down 20% from $2.48M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of NYMX and 5 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 5 added.

The largest buyer was Marshall Wace, opening a new position worth an estimated $83.7K. The largest seller was Marathon Capital Management, exiting entirely with an estimated $179K sold.

  • 29 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q4 2016, down from 30 in Q3 2016.
  • Funds reported $1.99M of Nymox Pharmaceutical Corp stock for Q4 2016, down 20% quarter-over-quarter.
  • 5 funds opened new Nymox Pharmaceutical Corp positions in Q4 2016 and 6 closed out, a net change of -1 holder.
  • The largest Nymox Pharmaceutical Corp buyer in Q4 2016 was Marshall Wace, an estimated $83.7K added.
  • The largest Nymox Pharmaceutical Corp seller in Q4 2016 was Marathon Capital Management, an estimated $179K sold.

Based on aggregated 13F filings for Q4 2016.